Literature DB >> 31683032

Comparative health risk assessment of realgar and NiuHuangJieDu tablets based on tissue arsenic levels after multiple oral administration to rats.

Xiao Wu1, Rong Guan2, Yuexin Liu2, Shanhu Wu2, Min Song3, Taijun Hang4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Realgar (As2S2), a mineral traditional Chinese medicine (TCM), is proved to have great therapeutic effects in clinic and has been widely used in China for hundreds of years. As one of the most popular realgar-containing TCMs, NiuHuangJieDu Tablets (NHJDT) is used as OTC (over-the-counter) drug in daily life for fever relieving, detoxicating, as well as cure of sore throat and gingival swelling. However, the safety of realgar and its-containing TCMs still remains unclear. AIM OF THE STUDY: This study was to investigate the accumulation of arsenic in rat body and evaluate the safety of realgar-containing TCMs in vivo.
MATERIALS AND METHODS: The health risk of arsenic was evaluated in rats by tissue distribution and histopathology, as well as arsenic speciation in plasma after multiple oral gavage of low and high doses of realgar and NiuHuangJieDu Tablets (NHJDT), respectively. Total arsenic and arsenic speciation were determined by hydride generation-atomic fluorescence spectrometry (HG-AFS) and high performance liquid chromatography-hydride generation-atomic fluorescence spectrometry (HPLC-HG-AFS), respectively.
RESULTS: Arsenic accumulated in rat tissues especially in heart, liver, spleen, lung, kidney, uterus and ovary. Dimethylarsenic acid (DMA) was detected as the predominant species in rat plasma after dosing. In comparison of realgar, NHJDT with co-existing components significantly alleviated tissues injury, and reduced arsenic concentration in rat tissues and plasma.
CONCLUSIONS: NHJDT with co-existing components combination was relatively safer than realgar, but the accumulation of arsenic was still significant after long-term medication. Therefore, great attentions should be paid to realgar-containing TCMs to avoid toxicity from arsenic accumulation. Moreover, the dose regimen of realgar-containing TCMs should be designed rationally for clinical application. These results may provide useful references for the application of realgar-containing TCMs and might be helpful for the understanding of TCM compound compatibility.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arsenic; Health risk assessment; NiuHuangJieDu tablets; Realgar; Tissue distribution

Mesh:

Substances:

Year:  2019        PMID: 31683032     DOI: 10.1016/j.jep.2019.112370

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Compatibility of Niuhuang Jiedu Tablets Results in Attenuated Arsenic Bioaccumulation and Consequent Protection against Realgar-Induced Toxicity in Mice.

Authors:  Wenfeng Xu; Shuo Xu; Yongmei Kuang; Xiaorong He; Pengfei Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

2.  An Experimental Study Reveals the Protective Effect of Autophagy against Realgar-Induced Liver Injury via Suppressing ROS-Mediated NLRP3 Inflammasome Pathway.

Authors:  Jing Yang; Jian Li; Haoqi Guo; Yuwei Zhang; Ziwei Guo; Yu Liu; Taoguang Huo
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

3.  Comparative pharmacokinetics and urinary excretion of arsenic and mercury after oral administration of realgar, cinnabar and AnGongNiuHuang Pill to rats.

Authors:  Xiao Wu; Zeling Zhong; Kuangmin Lin; Xinhe Liu; Zhichao Wu; Zitian Liu; Yongming Li
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

4.  Ursodeoxycholic Acid Protects Against Arsenic Induced Hepatotoxicity by the Nrf2 Signaling Pathway.

Authors:  Chao Li; Sheng Zhang; Liming Li; Qing Hu; Shen Ji
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

5.  Arsenic-Related Health Risk Assessment of Realgar-Containing NiuHuangJieDu Tablets in Healthy Volunteers Po Administration.

Authors:  Xiao Wu; Ruoning Yan; Rong Guan; Yi Du; Yuexin Liu; Shanhu Wu; Song Zhu; Min Song; Taijun Hang
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.